Hospira’s Mayne Event: Acquisition Strengthens Oncology Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
Merger will create the leading generic injectable pharmaceutical company in the world.
You may also be interested in...
Hospira Hinges Emerging Market Success On Scale And Differentiation
Hospira Inc.'s new CEO Michael Ball laid out the company's strategic moves to expand in the fast-growing emerging markets during the company's Sept. 7 Investor's Day conference. The CEO said the U.S.-centric company's future growth hinges on expanding its footprint in emerging markets and launching more products including biosimilars in top pharmaceutical markets in Europe and Japan
FTC Clearance Of Hospira’s Mayne Acquisition Hinges On Generic Divestitures
Firm must sell five generic injectable drugs to Barr under FTC consent order to complete $2 billion acquisition of Australian company.
FTC Clearance Of Hospira’s Mayne Acquisition Hinges On Generic Divestitures
Firm must sell five generic injectable drugs to Barr under FTC consent order to complete $2 billion acquisition of Australian company.